* Summit Therapeutics Inc reported a quarterly adjusted loss of 8 cents per share for the quarter ended September 30. The mean expectation of three analysts for the quarter was for a loss of 7 cents per share. Wall Street expected results to range from -7 cents to -6 cents per share.
* Reported revenue was zero; analysts expected zero.
* Summit Therapeutics Inc's reported EPS for the quarter was a loss of 8 cents.
* The company reported a quarterly loss of $56.3 million.
* Summit Therapeutics Inc shares had fallen by 0.3% this quarter and gained 736.4% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 0.3% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Summit Therapeutics Inc is $40.00 This summary was machine generated from LSEG data October 30 at 03:21 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.07 -0.08 Missed
Jun. 30 2024 -0.06 -0.09 Missed
Mar. 31 2024 -0.06 -0.06 Met
Comments